Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Atémpero IDI-20080283 | Other Identifier | VEGENAT, S.A. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to evaluate the beneficial effects of the administration of enteral nutrition product with milk proteins, monounsaturated fatty acids and low dextrose equivalent maltodextrin and enriched in eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and medium chain triglycerides (MCT) in patients with mild acute pancreatitis. All this against other specific product.
The main objectives of this project are:
Oral administration of an oligomeric formula with milk proteins, mainly whey protein partially hydrolysate, monounsaturated fatty acids (AGM) and low dextrose equivalent maltodextrin and enriched in polyunsaturated fatty acids (PUFA) of omega-3 series, EPA and DHA, and MCT designed for nutritional support of patients with compromised intestinal function, to maintain or improve nutritional status and reduce the inflammatory response in undernourished patients with mild acute pancreatitis, compared with oligomeric enteral nutrition product, low in fat and rich in glutamine.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental Group | Experimental | Patients of this group will receive 400 ml per day of T-Diet plus Atémpero product during 28 days. |
|
| Control Diet | Active Comparator | Patients of this group will receive 2 packets (76 g) per day of AlitraQ (Abbott) product during 28 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| T-Diet plus Atémpero | Dietary Supplement | T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis. |
| Measure | Description | Time Frame |
|---|---|---|
| Acceptance, Tolerance and Nutritional Status |
| 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Inflammatory parameters evolution and EN complications |
| 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Cristina Velasco Gimeno, BA | Contact | +34 91 586 71 64 | cvelasco.hgugm@salud.madrid.org |
| Name | Affiliation | Role |
|---|---|---|
| Pilar GarcÃa-Peris, PhD | Hospital Universitario Gregorio Marañón | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Nutrition and Dietetic Unit, Hospital Universitario Gregorio Marañón | Recruiting | Madrid | Madrid | 28007 | Spain |
Not provided
| ID | Term |
|---|---|
| D010195 | Pancreatitis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D010645 | Phentermine |
| ID | Term |
|---|---|
| D000662 | Amphetamines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D000588 | Amines |
| D009930 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| AlitraQ (Abbott) | Dietary Supplement | AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine. |
|
|
| Organic Chemicals |